China: How to strategise and win in the world's fastest changing healthcare market
In this paper, our experts Marc Yates, Pei Li Teh and Brett Gardiner discuss the China healthcare reforms which affect pharma and propose how to build the market understanding required to launch a brand effectively in this exciting region.
With a population of 1.4 billion people China has always been an attractive prize to the pharmaceutical industry. However, China has historically been a tough market to crack and few multinational companies have seen a good return on their investment. But in 2019, the 70th anniversary of the communist party’s victory, the outlook has changed completely and now pharma is rushing to leverage the many opportunities that China offers.
Are dual ARVs the new frontier in a maturing HIV market?
Tackling and managing HIV has been one of the pharmaceutical industry’s more distinguished achievements, despite the turbulence and antagonism that marked the early days of AIDS-related R&D and the industry’s relationships with governments, patients and activists.
Therapy Watch Associate Director Raquel Nuñez, discusses continuing improvements in HIV therapies and the evolution of single-tablet regimens (STRs) over time.
Patient centricity: Reality or rhetoric?
Everybody is talking about patient centricity, but what does it mean for those involved in market research, insights and business intelligence?
The term has certainly begun to filter through to the pharmaceutical market research industry. It was a hot topic at EphMRA conference in 2017, with a number of presentations from agencies, including some innovative new research offerings.
Punching above your weight: Combining behavioural and attitudinal data to strengthen segmentations
In this paper we examine the differences between behavioural and attitudinal approaches to segmentation and outline how integration of the two can best be achieved to strengthen segmentation solutions
Segmentation solutions in healthcare are experiencing a welcome comeback. But there appear to be two camps emerging - one camp are proponents of the 'behavioural' segmentation based on secondary sales, script or similar data; the other believe that 'attitudinal' segmentations must be based on primary market research to accurately delineate segment membership, definition and the "whys" that underpin the findings. It's time to take off the gloves and look at the argument from both sides.
South Korea: The next global player?
In this paper, we will explore some of the key trends and outlooks for South Korea in more detail, including what lies behind its presence at the extremes of two conflicting global health indicators: longest life expectancy and highest suicide rates.
Over the past two decades South Korea has experienced rapid economic growth. Low unemployment, rising incomes and increased health insurance coverage have all contributed to the development of a robust healthcare sector and catalysed pharmaceutical sales. South Korea is currently the 13th largest pharmaceutical market in the world and the third largest in Asia, with predicted compound annual growth rate (CAGR) of 2.4%. increasing from US$18.6 billion in 2016 to US$20.4 billion by 2020.